• Advances in the Understanding of Etiology (I)
• 30 min
  1. Infection and autoimmunity: a two-way relationship

  • Dr. Ricard Cervera
• 35 min
  2. Autoimmunity and atherosclerosis

  • Prof. Johan Frostegard
• 47 min
  3. Endothelium and autoimmunity

  • Prof. Pier Luigi Meroni
• Advances in the Understanding of Etiology (II)
• 22 min
  4. Prolactin has a pathogenic role in systemic lupus erythematosus

  • Prof. Luis Jara-Quezada
• 44 min
  5. Sjögren's syndrome: current knowledge and future prospects

  • Prof. Athanasios G. Tzioufas
• 51 min
  6. Genetic and environmental triggers of autoimmune thyroid diseases

  • Prof. Yaron Tomer
• Advances in Pathogenesis and Clinical Manifestation
• 38 min
  7. The catastrophic antiphospholipid syndrome and the microangiopathic antiphospholipid syndrome

  • Prof. Ronald Asherson
• 20 min
  8. Pathogenic mechanisms of autoantibodies: circulating and local antibodies that form immune complexes

  • Dr. Luís Eduardo Coelho Andrade
• 34 min
  9. Pathogenic mechanisms of autoantibodies: antibodies to intracellular and membrane-bound antigens

  • Dr. Luís Eduardo Coelho Andrade
• 43 min
  10. What causes primary biliary cholangitis?

  • Dr. M. Eric Gershwin
• 30 min
  11. Capillaroscopy in autoimmune rheumatic diseases

  • Prof. Maurizio Cutolo
• Advances in Diagnostic Methodologies (I)
• 26 min
  12. The past, present & future of ANA testing: history and challenges of ANA

  • Prof. Marvin J. Fritzler
• 33 min
  13. The past, present & future of ANA testing: changing bandwidth and future of ANA

  • Prof. Marvin J. Fritzler
• 36 min
  14. Diagnostic methods in autoimmunity

  • Mr. Steven Binder
• 24 min
  15. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 1

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 28 min
  16. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 2

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 48 min
  17. Novel aspects of systemic sclerosis

  • Prof. Gabriele Valentini
• Advances in Diagnostic Methodologies (II)
• 46 min
  18. An update on the multiple faces of celiac disease

  • Prof. Aaron Lerner
• 23 min
  19. Protective autoantibodies

  • Prof. Elias Toubi
• 32 min
  20. CD44 genetic deletion enhances and CD44 antibody targeting attenuates autoimmune inflammation

  • Prof. David Naor
• 44 min
  21. Rheumatic fever: a model of a post-infectious autoimmune disease

  • Prof. Jorge Kalil
• Treatments of autoimmune diseases
• 38 min
  22. Intravenous immunoglobulins: clinical evidence

  • Prof. Shaye Kivity
• Latest Developments in the Field
• 26 min
  23. Adjuvants and autoimmunity

  • Dr. Eitan Israeli
• 46 min
  24. Antiphospholipid syndrome (APS): from pathogenesis to treatment

  • Prof. Roger Levy
• 24 min
  25. Vitamin D and autoimmunity

  • Dr. Shir Azrielant
• 28 min
  26. Pregnancy in rheumatic diseases

  • Prof. Pier Luigi Meroni
• Archived Lectures *These may not cover the latest advances in the field
• 47 min
  27. Pathogenic mechanisms of autoantibodies

  • Prof. Cees Kallenberg
• 41 min
  28. B lymphocytes on the frontline of autoimmunity

  • Prof. Pierre Youinou
• 42 min
  29. Apoptotic cell clearance deficiency

  • Prof. Martin Herrmann
• 34 min
  30. Auto-antibodies as predictors of autoimmune disease

  • Dr. Nicola Bizzaro
• 46 min
  31. Innate immunity and natural autoantibodies

  • Prof. Luc Mouthon
• 45 min
  32. Accelerated atherosclerosis in autoimmune rheumatic disease

  • Dr. Andrea Doria
• 47 min
  33. Pregnancy in autoimmune rheumatic diseases

  • Prof. Angela Tincani
• 42 min
  34. Pulmonary hypertension in the connective tissue disease pathogenesis, clinical features and therapeutic options in 2006

  • Prof. Ronald Asherson
• 39 min
  35. Use of algorithms for high quality diagnostics and handling of patients with autoimmune rheumatic diseases

  • Dr. Allan Wiik
• 24 min
  36. Immunologic mechanisms in systemic lupus erythematosus

  • Prof. Kok-Yong Fong
• 23 min
  37. Osteoimmunology

  • Prof. João Eurico Fonseca
  • Ms. Joana Caetano-Lopes
• 43 min
  38. ANCA-associated systemic vasculitides

  • Prof. Loic Guillevin
• 23 min
  39. The common origin for diverse autoimmune diseases

  • Prof. Juan-Manuel Anaya
• 76 min
  40. Anti-cytokine therapy in rheumatoid arthritis

  • Prof. Piercarlo Sarzi-Puttini
• 40 min
  41. Sjogren's syndrome: autoimmune epithelitis

  • Prof. Haralampos Moutsopoulos
• 31 min
  42. Vitamin D and autoimmunity

  • Dr. Howard Amital
• 25 min
  43. Intravenous immunoglobulins: myth and reality

  • Prof. Zera Tellier

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Molecular redundancy
3. Redundant molecules replace disrupted genes
4. Genomic structure of the CD44 molecule
5. CD44 - alternative splicing
6. CD44 ligands
7. Dr. Lora Eshkar Sebban
8. CD44 functions
9. The three steps model of Dr. Springer
10. Rolling and migration of CD44-positive cells
11. The migration process
12. Anti-CD44 mAbs reduce pathological activities
13. Anti-CD44 mAbs reduce diabetogenic activity
14. Anti-CD44 mAbs reduce arthritic activity
15. Generation of CIA model experimental protocol
16. In-vivo efficacy in CIA model
17. The CD44-dependency of CIA
18. CIA is a CD44-dependent disease
19. Effect of type 2 collagen injection
20. CD44 DNA analysis of CD44-deficient mice
21. Flow cytometry: CD44-deficient mice spleen cells
22. Sensitivity to CIA: CD44-knockout vs. WT mice
23. Histopathology of joints from CD44+/+ and -/- mice
24. Photo imaging of histochemical staining revealed
25. CD44-deficient mice: hyaluronic acid accumulation
26. Anti-CD44 mAb inhibits CIA in WT DBA/1 mice
27. Support of collagen-induced arthritis in mice
28. Inhibition of CIA by hyaluronidase in WT mice
29. Inhibition of CIA in WT and CD44-K/O mice
30. CD44-deficient spleen cells bind to HA
31. HA-binding protein compensates for CD44 in mice
32. The HA binding protein that compensates for CD44
33. RHAMM: receptor for hyaluronan-mediated motility
34. RHAMM reagents
35. RHAMM regulation in CD44-deficient mice (1)
36. RHAMM regulation in CD44-deficient mice (2)
37. Transwell migration assay
38. Spleen cells migration from CD44-deficient mice
39. Anti-RHAMM inhibits mice spleen cells migration
40. Anti-RHAMM mAb and soluble RHAMM inhibit CIA
41. CD44 affect the disease activity
42. CD44 deletion affect embryonic development
43. RHAMM regulation after CD44 genetic deletion
44. RHAMM functions
45. Interpretation of the redundancy mechanism
46. Disease-specific CD44 (1)
47. Disease-specific CD44 (2)
48. Exploring CD44 isoforms
49. Genomic sequence of: V4/V5 junction, CD44vRA
50. Single amino acid exchange and proteins function
51. Levels of CD44vRA Abs in mice splenocytes
52. Binding F8:33 anti-CD44 mAb to synovial cells
53. Synovial fluid cells from an RA and OA patient
54. F8:33 anti-CD44vRA mAb bindings
55. Does anti-CD44vRA Ab promote apoptosis?
56. Anti-CD44vRA mAb induces apoptosis in RA (1)
57. Anti-CD44vRA mAb induces apoptosis in RA (2)
58. Disease-specific CD44
59. Conclusions
60. Acknowledgements
61. Albert Einstein's wisdom...
62. References
63. References

Topics Covered

• CD44 and RHAMM (receptor for hyaluronan-mediated motility) are cell adhesion and cell homing receptors
• Cell migration
• Generation of different CD44 isoforms
• RHAMM also supports cell motility and is engaged in intracellular signalling
• Collagen-induced arthritis and type 1 diabetes are CD44-dependent pathologies
• Molecular redundancy
• CD44 targeting by anti-CD44 mAb may eradicate not only malignant cells and destructive inflammatory cells but also CD44-expressing normal cells which are committed to physiological functions

Links

Series:

• Autoimmunity

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Naor, D. (2017, November 28). CD44 genetic deletion enhances and CD44 antibody targeting attenuates autoimmune inflammation [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 19, 2024, from https://hstalks.com/bs/213/.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Reviewed on November 28, 2017

Financial Disclosures

• Prof. David Naor has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.